Frovatriptan
Frova, Frovatriptan (frovatriptan) is a small molecule pharmaceutical. Frovatriptan was first approved as Frova on 2001-11-08. It is used to treat migraine disorders in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 1D and 5-hydroxytryptamine receptor 1B. In addition, it is known to target 5-hydroxytryptamine receptor 1A.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
Trade Name
FDA
EMA
Frova, Frovatriptan (discontinued: Frovatriptan)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| frova | New Drug Application | 2018-08-27 |
| frovatriptan | ANDA | 2024-12-12 |
| frovatriptan succinate | ANDA | 2019-12-31 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| migraine disorders | EFO_0003821 | D008881 | G43 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
31 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | 4 | 2 | 8 | 14 |
| Headache | D006261 | — | R51 | — | 1 | 1 | 1 | 1 | 4 |
| Premenstrual syndrome | D011293 | — | N94.3 | — | — | — | 1 | 1 | 2 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | 1 | — | 1 |
| Hernia | D006547 | — | K40-K46 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | 1 | — | — | 1 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | — | 1 | — | — | 1 |
| Disease progression | D018450 | — | — | — | — | 1 | — | — | 1 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | — | 1 | — | — | 1 |
| Sclerosis | D012598 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Secondary headache disorders | D051271 | — | — | — | 1 | — | — | — | 1 |
| Prescription drug overuse | D000067490 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | — | 2 | 2 |
| Neoplasms | D009369 | — | C80 | — | — | — | — | 1 | 1 |
| Bone neoplasms | D001859 | EFO_0003820 | D16 | — | — | — | — | 1 | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | — | — | — | 1 | 1 |
| Bone marrow diseases | D001855 | — | — | — | — | — | — | 1 | 1 |
| Keratoconus | D007640 | EFO_0004223 | H18.6 | — | — | — | — | 1 | 1 |
| Airway management | D058109 | — | — | — | — | — | — | 1 | 1 |
| Personal protective equipment | D000067393 | — | — | — | — | — | — | 1 | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | — | 1 | 1 |
| Metabolic diseases | D008659 | EFO_0000589 | E88.9 | — | — | — | — | 1 | 1 |
Show 13 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Frovatriptan |
| INN | frovatriptan |
| Description | Frovatriptan, sold under the brand name Frova, is a triptan drug developed by Vernalis for the treatment of migraine headaches and for short term prevention of menstrual migraine. The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe.
|
| Classification | Small molecule |
| Drug class | antimigraine agents (5-HT1 receptor agonists); sumatriptan derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN[C@@H]1CCc2[nH]c3ccc(C(N)=O)cc3c2C1 |
Identifiers
| PDB | — |
| CAS-ID | 158747-02-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1279 |
| ChEBI ID | — |
| PubChem CID | 77992 |
| DrugBank | DB00998 |
| UNII ID | H82Q2D5WA7 (ChemIDplus, GSRS) |
Target
Agency Approved
HTR1D
HTR1D
HTR1B
HTR1B
Organism
Homo sapiens
Gene name
HTR1D
Gene synonyms
HTR1DA, HTRL
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 1D
Protein synonyms
5-HT-1D, 5-HT-1D-alpha, 5-hydroxytryptamine (serotonin) receptor 1D, G protein-coupled, Serotonin 1D alpha receptor, Serotonin receptor 1D
Uniprot ID
Mouse ortholog
Htr1d (15552)
5-hydroxytryptamine receptor 1D (Q8BUW7)
Alternate
HTR1A
HTR1A
Organism
Homo sapiens
Gene name
HTR1A
Gene synonyms
ADRB2RL1, ADRBRL1
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 1A
Protein synonyms
5-HT1a receptor, 5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled, G-21, guanine nucleotide-binding regulatory protein-coupled receptor, Serotonin receptor 1A
Uniprot ID
Mouse ortholog
Htr1a (15550)
5-hydroxytryptamine receptor 1A (Q8BGS4)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Frovatriptan
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 814 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
357 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use